Stakeholders are pushing the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act as an offset for renewing CHIP funding, multiple industry stakeholders tell Inside Health Policy . The generic lobby plans to step up its advocacy on the bill, but the head of the trade group tells IHP that opponents are girding for a fight over the measure. CREATES would let generic drug companies sue brands to restrain them from blocking access to drug samples needed...